NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $0.08 -0.01 (-6.63%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.08 +0.00 (+2.97%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adaptimmune Therapeutics Stock (NASDAQ:ADAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADAP alerts:Sign Up Key Stats Today's Range$0.07▼$0.0850-Day Range$0.08▼$0.3552-Week Range$0.07▼$1.33Volume26.02 million shsAverage Volume48.68 million shsMarket Capitalization$20.54 millionP/E RatioN/ADividend YieldN/APrice Target$1.35Consensus RatingHold Company Overview Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Read More Adaptimmune Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreADAP MarketRank™: Adaptimmune Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 544th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageAdaptimmune Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptimmune Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.46% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 8.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.46% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 8.92%, indicating that investor sentiment is improving significantly. News and Social Media1.6 / 5News Sentiment-0.20 News SentimentAdaptimmune Therapeutics has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.74% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Stock News HeadlinesAdaptimmune Therapeutics (ADAP) Expected to Announce Quarterly Earnings on Monday3 hours ago | americanbankingnews.comAdaptimmune Announces Termination of Chief Medical OfficerAugust 9 at 8:32 PM | theglobeandmail.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | Brownstone Research (Ad)Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&AAugust 6, 2025 | seekingalpha.comHC Wainwright Brokers Decrease Earnings Estimates for ADAPAugust 2, 2025 | americanbankingnews.comLeerink Partnrs Has Bearish Estimate for ADAP Q2 EarningsAugust 2, 2025 | americanbankingnews.comAdaptimmune Sells Cell Therapy Assets for $55 MillionJuly 31, 2025 | msn.comHC Wainwright & Co. Downgrades Adaptimmune Therapeutics plc - Depositary Receipt () (ADAP)July 30, 2025 | msn.comSee More Headlines ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.5387 at the beginning of the year. Since then, ADAP shares have decreased by 85.6% and is now trading at $0.0775. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC (NASDAQ:ADAP) released its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). The biotechnology company had revenue of $7.29 million for the quarter, compared to the consensus estimate of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative trailing twelve-month return on equity of 163.73%. Read the conference call transcript. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' top institutional shareholders include Clear Harbor Asset Management LLC (0.05%). Insiders that own company stock include Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, Elliot Norry and John Lunger. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/13/2025Today8/09/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year FoundedN/APrice Target and Rating Average Price Target for Adaptimmune Therapeutics$1.35 High Price Target$3.00 Low Price Target$0.46 Potential Upside/Downside+1,644.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.81 million Net Margins-38.91% Pretax Margin-36.89% Return on Equity-163.73% Return on Assets-23.65% Debt Debt-to-Equity Ratio4.24 Current Ratio2.02 Quick Ratio1.79 Sales & Book Value Annual Sales$179.64 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book1.55Miscellaneous Outstanding Shares265,052,000Free Float231,284,000Market Cap$20.54 million OptionableOptionable Beta2.18 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ADAP) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.